Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Inclusion Criteria: * Must have histologically confirmed metastatic solid tumor; the malignancy should be considered incurable using standard treatment * Patients are not required to have HER-2 over-expression to be on this study * If the patient has had HER-2 expression measured prior to enrollment, the report alone will be accepted * If the patient has not had HER-2 expression measured prior to enrollment on this study tumor tissue blocks and/or freshly isolated tissue must be available for determination of HER-2 expression * Patients are not required to have epidermal growth factor receptor (EGFR) over-expression to be on this study * If the patient has had EGFR expression measured prior to enrollment, the report alone will be accepted * If the patient has not had EGFR expression measured prior to enrollment on this study tumor tissue blocks and/or freshly isolated tissue must be available for determination of EGFR expression * Patients with prior history of treated brain metastases who are off steroids and have stable metastatic brain disease for at least 3 months are eligible * Patients must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * White blood cells \> 3500/mm\^3 * Platelet count \> 100,000/mm\^3 * Serum bilirubin \< 1.5 mg %, regardless of whether patients have liver involvement secondary to tumor * Alanine aminotransferase (ALT) must be \< 2 times upper limit of normal * Creatinine \< 1.5 mg/dL or ca…